Generic name · Autoimmune / Anti-TNF
Adalimumab J-Code / HCPCS Code
In short
Adalimumab is billed under HCPCS J0135 — Injection, adalimumab, 20 mg. One billing unit is 20 mg.
Adalimumab is usually self-administered and dispensed through a pharmacy benefit. Adalimumab biosimilars are listed under their own names.
Reference
- Code
- J0135 — Injection, adalimumab, 20 mgMed-Code curated
- Billing unit
- 20 mg
- Same code in the directory
- Humira
- Pharmacologic class
- Tumor Necrosis Factor BlockerFrom the FDA listings below
- Labelers
- A-S Medication Solutions; AbbVie Inc.; Amgen USA Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; CELLTRION USA, Inc.; Coherus BioSciences Inc; Cordavis Limited; Fresenius Kabi USA, LLCand 6 more
- J-code category
- Autoimmune / Anti-TNF
FDA-listed products
Finished products whose name and route match this directory entry.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Amjevitaadalimumab-atto | Adalimumab 20 mg/.2mL | InjectionSubcutaneous | Amgen USA Inc. | 72511-399 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.8mL | InjectionSubcutaneous | Amgen USA Inc. | 72511-400 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.4mL | InjectionSubcutaneous | Amgen USA Inc. | 72511-479 |
| Hyrimozadalimumab-adaz | Adalimumab 40 mg/.4mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-100 |
| Amjevitaadalimumab-atto | Adalimumab 80 mg/.8mL | InjectionSubcutaneous | Amgen USA Inc. | 72511-481 |
| Hyrimozadalimumab-adaz | Adalimumab 40 mg/.4mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-101 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.4mL | InjectionSubcutaneous | Amgen USA Inc. | 72511-482 |
| Hyrimozadalimumab-adaz | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-102 |
| Hyrimozadalimumab-adaz | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-103 |
| Hyrimozadalimumab-adaz | Adalimumab 80 mg/.8mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-107 |
| Hyrimozadalimumab-adaz | Adalimumab 20 mg/.2mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-108 |
| Hyrimozadalimumab-adaz | Adalimumab 80 mg/.8mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-113 |
| Adalimumab-bwwd | Adalimumab 40 mg/.4mL | SolutionSubcutaneous | Cordavis Limited | 83457-186 |
| Adalimumab-bwwd | Adalimumab 40 mg/.4mL | SolutionSubcutaneous | Cordavis Limited | 83457-187 |
| Yusimryadalimumab-aqvh | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Meitheal Pharmaceuticals Inc. | 71288-815 |
| Yusimryadalimumab-aqvh | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Meitheal Pharmaceuticals Inc. | 71288-816 |
| Yusimryadalimumab-aqvh | Adalimumab 40 mg/.4mL | Injection, SolutionSubcutaneous | Meitheal Pharmaceuticals Inc. | 71288-817 |
| Yusimryadalimumab-aqvh | Adalimumab 80 mg/.8mL | Injection, SolutionSubcutaneous | Meitheal Pharmaceuticals Inc. | 71288-818 |
| Yusimryadalimumab-aqvh | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Coherus BioSciences Inc | 70114-210 |
| Yusimryadalimumab-aqvh | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Coherus BioSciences Inc | 70114-220 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.8mL | SolutionSubcutaneous | Organon LLC | 78206-183 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.8mL | SolutionSubcutaneous | Organon LLC | 78206-184 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.8mL | SolutionSubcutaneous | Organon LLC | 78206-185 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.4mL | SolutionSubcutaneous | Organon LLC | 78206-186 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.4mL | SolutionSubcutaneous | Organon LLC | 78206-187 |
| Amjevitaadalimumab-atto | Adalimumab 20 mg/.2mL | InjectionSubcutaneous | Nuvaila Limited | 84612-399 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.4mL | InjectionSubcutaneous | Nuvaila Limited | 84612-479 |
| Amjevitaadalimumab-atto | Adalimumab 80 mg/.8mL | InjectionSubcutaneous | Nuvaila Limited | 84612-481 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.4mL | InjectionSubcutaneous | Nuvaila Limited | 84612-482 |
Other products with this name
Same name but a different route, formulation or combination — the code above does not apply to these.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Cyltezoadalimumab-adbm | — | Kit | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0375 |
| Humiraadalimumab | — | Kit | AbbVie Inc. | 0074-2540 |
| Abriladaadalimumab-afzb | — | Kit | Pfizer Laboratories Div Pfizer Inc | 0025-0333 |
| Hyrimozadalimumab-adaz | — | Kit | Cordavis Limited | 83457-112 |
| Humiraadalimumab | — | Kit | Cordavis Limited | 83457-124 |
| Humiraadalimumab | — | Kit | Cordavis Limited | 83457-243 |
| Humiraadalimumab | — | Kit | Cordavis Limited | 83457-554 |
| Abriladaadalimumab-afzb | — | Kit | A-S Medication Solutions | 50090-8032 |
| Humiraadalimumab | — | Kit | Cordavis Limited | 83457-616 |
| Humiraadalimumab | — | Kit | Cordavis Limited | 83457-817 |
| Humiraadalimumab | — | Kit | AbbVie Inc. | 0074-0554 |
| Adalimumabadalimumab-aaty | — | Kit | CELLTRION USA, Inc. | 72606-022 |
| Cyltezoadalimumab-adbm | — | Kit | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0400 |
| Yuflymaadalimumab-aaty | — | Kit | CELLTRION USA, Inc. | 72606-023 |
| Yuflymaadalimumab-aaty | — | Kit | CELLTRION USA, Inc. | 72606-030 |
| Adalimumabadalimumab-aaty | — | Kit | CELLTRION USA, Inc. | 72606-040 |
| Cyltezoadalimumab-adbm | — | Kit | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0405 |
| Adalimumabadalimumab-aaty | — | Kit | CELLTRION USA, Inc. | 72606-041 |
| Humiraadalimumab | — | Kit | AbbVie Inc. | 0074-0616 |
| Humiraadalimumab | — | Kit | AbbVie Inc. | 0074-3799 |